{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Health+Tag&page=12", "query": { "intervention": "Health Tag", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 535, "total_pages": 54, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Health+Tag&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Health+Tag&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T05:45:47.889Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03486873", "title": "Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Solid Tumors", "Hematologic Malignancies" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Standard of Care (SOC)", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "MK-4280", "type": "DRUG" }, { "name": "MK-4280A", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab (+) Berahyaluronidase alfa", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3500, "start_date": "2018-08-21", "completion_date": "2043-08-04", "has_results": false, "last_update_posted_date": "2026-10-29", "last_synced_at": "2026-11-02T05:45:47.889Z", "location_count": 65, "location_summary": "Tucson, Arizona • Bakersfield, California • Fresno, California + 56 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03486873" }, { "nct_id": "NCT04592380", "title": "Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dyspnea", "Hypertension", "Acute Heart Failure" ], "interventions": [ { "name": "Stage 1: Clevidipine (double-blinded)", "type": "DRUG" }, { "name": "Stage 1: Placebo (double-blinded)", "type": "DRUG" }, { "name": "Stage 2: Clevidipine (open-label)", "type": "DRUG" }, { "name": "Stage 2: Standard of Care (open-label)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Medicines Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2014-08", "completion_date": "2016-11", "has_results": false, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-11-02T05:45:47.889Z", "location_count": 9, "location_summary": "Montgomery, Alabama • Tucson, Arizona • St Louis, Missouri + 5 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Brooklyn", "state": "New York" }, { "city": "Brooklyn", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04592380" }, { "nct_id": "NCT01835379", "title": "Study of Oasis Ultra in Diabetic Foot Ulcers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetic Foot Ulcer" ], "interventions": [ { "name": "Oasis", "type": "DEVICE" }, { "name": "Standard", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "OTHER" ], "sponsor": "Healthpoint", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2013-05", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2015-01-22", "last_synced_at": "2026-11-02T05:45:47.889Z", "location_count": 16, "location_summary": "Little Rock, Arkansas • Carlsbad, California • Fair Oaks, California + 12 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Carlsbad", "state": "California" }, { "city": "Fair Oaks", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01835379" }, { "nct_id": "NCT03564691", "title": "Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "MK-4830", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "MK-4830A", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 470, "start_date": "2018-07-11", "completion_date": "2025-09-26", "has_results": false, "last_update_posted_date": "2025-10-07", "last_synced_at": "2026-11-02T05:45:47.889Z", "location_count": 9, "location_summary": "San Francisco, California • Detroit, Michigan • St Louis, Missouri + 6 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03564691" }, { "nct_id": "NCT03125278", "title": "Patient Knowledge of Medication Indication", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Medical Audit" ], "interventions": [ { "name": "Medication knowledge", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "HealthPartners Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2017-04-11", "completion_date": "2017-10-31", "has_results": false, "last_update_posted_date": "2018-06-07", "last_synced_at": "2026-11-02T05:45:47.889Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Saint Paul, Minnesota", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03125278" }, { "nct_id": "NCT01162304", "title": "Open-Label Trial Comparing Oxycodone Medications", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Pain" ], "interventions": [ { "name": "Extended Release Oxycodone", "type": "DRUG" }, { "name": "Immediate Release Oxycodone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 18, "start_date": "2010-03", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2015-07-17", "last_synced_at": "2026-11-02T05:45:47.889Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01162304" }, { "nct_id": "NCT04762771", "title": "Colchicine for the Treatment of Cardiac Injury in Hospitalized Patients With COVID-19 (COLHEART-19)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Covid19" ], "interventions": [ { "name": "Colchicine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baptist Health South Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 2, "start_date": "2020-12-23", "completion_date": "2021-09-20", "has_results": true, "last_update_posted_date": "2022-07-25", "last_synced_at": "2026-11-02T05:45:47.889Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04762771" }, { "nct_id": "NCT04510649", "title": "Surufatinib DDI With a PPI and a CYP3A Inducer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Part A", "type": "DRUG" }, { "name": "Part B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hutchison Medipharma Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 28, "start_date": "2020-07-09", "completion_date": "2021-03-02", "has_results": false, "last_update_posted_date": "2021-06-18", "last_synced_at": "2026-11-02T05:45:47.889Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04510649" }, { "nct_id": "NCT03953820", "title": "Diazepam Buccal Film (DBF) - Diastat Rectal Gel (DRG) Crossover Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Epilepsy" ], "interventions": [ { "name": "Diazepam Buccal Film", "type": "DRUG" }, { "name": "Diastat® Rectal Gel (Valeant Pharmaceuticals USA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aquestive Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 31, "start_date": "2019-04-13", "completion_date": "2019-07-31", "has_results": true, "last_update_posted_date": "2020-08-18", "last_synced_at": "2026-11-02T05:45:47.889Z", "location_count": 3, "location_summary": "Miami, Florida • Orlando, Florida • Winter Park, Florida", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Winter Park", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03953820" }, { "nct_id": "NCT04165343", "title": "Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on EXPLORER", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non-Alcoholic Fatty Liver Disease (NAFLD)", "Nonalcoholic Steatohepatitis (NASH)" ], "interventions": [ { "name": "Positron Emission Tomography (PET) on EXPLORER", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "DIAGNOSTIC_TEST" }, { "name": "Echocardiogram and Electrocardiogram", "type": "DIAGNOSTIC_TEST" }, { "name": "Blood test", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "RADIATION", "DIAGNOSTIC_TEST" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2019-11-01", "completion_date": "2023-05-11", "has_results": false, "last_update_posted_date": "2023-09-01", "last_synced_at": "2026-11-02T05:45:47.889Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04165343" } ] }